PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration (“FDA”) for Teverelix®, its investigational, next generation, long-acting GnRH antagonist, in advanced prostate cancer (“APC”) patients at increased cardiovascular (“CV”) risk.